SCHEMBL12379632

SCHEMBL12379632

COc1cc(-c2ccccc2)cn2ncc(-c3csc(C(N)=O)c3)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAK O14976 1/20 0.43
JAK2 O60674 10/20 0.40
JAK1 P23458 10/20 0.40
TYK2 P29597 10/20 0.40
JAK3 P52333 10/20 0.40
HPGDS O60760 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
MARK3 P27448 3/20 0.38
KDR P35968 1/20 0.36
ULK1 O75385 1/20 0.36
ULK2 Q8IYT8 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
STK17A Q9UEE5 1/20 0.36
CDK2 P24941 1/20 0.36
IKBKE Q14164 1/20 0.36
AURKB Q96GD4 1/20 0.36
TBK1 Q9UHD2 1/20 0.36
IKBKB O14920 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2288466 0.92 GAK (0.43) GAKJAK2JAK1TYK2JAK3
SCHEMBL2288882 0.87 MARK3 (0.49) JAK2JAK1TYK2JAK3MARK3
SCHEMBL12418265 0.84 MMP12 (0.48) JAK2JAK1TYK2JAK3ALDH1A1
SCHEMBL12379636 0.83 MARK3 (0.46) MARK3ULK1ULK2MKNK2STK17A
SCHEMBL12419199 0.81 MARK3 (0.59) JAK2JAK1TYK2JAK3MARK3
SCHEMBL12379630 0.81 MARK3 (0.59) JAK2JAK1TYK2JAK3MARK3
SCHEMBL2291469 0.80 MARK3 (0.59) JAK2JAK1TYK2JAK3MARK3
SCHEMBL12461812 0.79 JAK1 (0.54) GAKJAK2JAK1TYK2JAK3
SCHEMBL12418680 0.77 MARK3 (0.54) JAK2JAK1TYK2JAK3MARK3
SCHEMBL12461270 0.77 KDR (0.53) GAKKDRMKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518911-B2 Pyrazolo[1,5-a]pyridines as MARK inhibitors MERCK SHARP & DOHME CORP. (US) 2013-08-27 US disclosed
US-8518911-B2 Pyrazolo[1,5-a]pyridines as MARK inhibitors MERCK SHARP & DOHME CORP. (US) 2013-08-27 US disclosed
EP-2320737-B1 PYRAZOLO-[1,5-A]-PYRIDINES AS MARK INHIBITORS MERCK SHARP & DOHME (US) 2013-07-17 EP disclosed
US-20110195933-A1 PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS MERCK SHARP & DOHME LLC 2011-08-11 US disclosed
US-20110195933-A1 PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS MERCK SHARP & DOHME LLC 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195933-A1 PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS MARK3, MARK4, MARK1 GAK 116/4885JAK2 1240/4885JAK1 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.